Upper gastrointestinal symptoms experienced by users of low-dose aspirin (Acetylsalicylic Acid) 75325mgday for primary and secondary coronary artery disease prevention: Perspectives from patient focus groups

Patient

Volumn 2, Issue 2, 2009, Pages 85-93

  Margolis, Mary Kay ^a   Halling, Katarina ^b   Sörstadius, Elisabeth ^b   Næsdal, Jørgen ^b   Manson, Stephanie ^a   Coyne, Karin ^a  

^a Center for Health Outcomes Research   (United States)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; AWARENESS; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; DOCTOR PATIENT RELATION; DRUG USE; EATING HABIT; EXPERIENCE; EXPLORATORY RESEARCH; FEMALE; FOOD; FRANCE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HEART PROTECTION; HEARTBURN; HUMAN; LIFE; LIFESTYLE; LOW DRUG DOSE; MALE; NAUSEA; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RISK FACTOR; SECONDARY PREVENTION; SPICE; STOMACH PAIN; STRESS; UNITED STATES; UPPER ABDOMINAL PAIN; UPPER GASTROINTESTINAL BLEEDING; UPPER GASTROINTESTINAL TRACT;

EID: 77953376219     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.2165/01312067-200902020-00004     Document Type: Article

References (24)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan 12; 324 (7329): 71-86
2. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004 Jan; 25 (2): 166-81
3. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis.N Engl J Med 2005 Dec 1; 353 (22): 2373-83
4. Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among US adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006 Jan; 30 (1): 74-7
5. Pignone M, Anderson GK, Binns K, et al. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007 May;32 (5): 403-7
6. Morant SV, McMahon AD, Cleland JG, et al. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.Br J Clin Pharmacol 2004 Feb; 57 (2): 188-98
7. Tran HA, Anand SS, Hankey GJ, et al. Aspirin resistance.Thromb Res 2007; 120 (3): 337-46
8. Shaya FT, El Khoury AC, Mullins CD, et al. Drug therapy persistence and stroke recurrence. Am J Manag Care 2006 Jun; 12 (6): 313-9
9. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004 Oct 19; 110 (16): 2361-7
10. Cotter G, Shemesh E, Zehavi M, et al. Lack ofaspirin effect:aspirin resistance or resistance to taking aspirin? Am Heart J 2004 Feb; 147 (2): 293-300
11. Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005 Feb 1; 45 (3): 456-9
12. Maulaz AB, Bezerra DC, Michel P, et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005 Aug; 62 (8): 1217-20
13. Brun J, Jones R. Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 2001 Jan 8; 110 (1A): 12S-3S
14. Ford AC, Forman D, Bailey AG, et al. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut 2007 Mar; 56 (3):321-7
15. Laheij RJ, Van Rossum LG, Jansen JB, et al. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo- controlled trial. Aliment Pharmacol Ther 2003 Jul 1; 18 (1): 109-15
16. Samarasinghe YP, Purcell I, Rivas-Toro H, et al. Costs of aspirin should include treatment costs for dyspepsia. Br J Cardiology 2007; 14 (3): 169-70
17. CAPRIE Steering Committee. A randomised, blinded, trial ofclopidogrel versus aspirin in patients at risk ofischaemic events (CAPRIE). Lancet 1996 Nov 16; 348 (9038): 1329-39
18. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004 Jan 1; 159 (1): 23-31
19. Serrano P, Lanas A, Arroyo MT, et al. Risk ofupper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002 Nov; 16 (11): 1945-53
20. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995 Apr 1; 310 (6983): 827-30
21. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005 Nov 1; 22 (9): 795-801
22. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk ofaspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996 Nov 23; 348 (9039): 1413-6
23. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006 Aug; 119 (8):624-38
24. Laheij RJ, Jansen JB, Verbeek AL, et al. Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease.Aliment Pharmacol Ther 2001 Jul; 15 (7): 1055-9